Phase II Clinical Trial of the MEK Inhibitor Trametinib With the AKT Inhibitor GSK2141795 in BRAF Wild-type Melanoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Feb 2017
Price : $35 *
At a glance
- Drugs Trametinib (Primary) ; Uprosertib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 18 Feb 2015 Planned End Date changed from 1 May 2018 to 1 May 2016, according to ClnicalTrials.gov record.